Spear Bio Inc., a Woburn, MA-based biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, closed a $45m Series A financing.
The round was co-led by Foresite Capital and Bio-Techne Corporation, with additional participation from existing investors including Maverick Ventures, Yonjin Capital and CDH Investments. Vikram Bajaj, Managing Director of Foresite Capital, has joined the company’s Board of Directors.
The funding will allow the company to accelerate its assay menu expansion and commercial offerings to solve challenges in protein research and early disease diagnostics.
Led by Dr. Feng Xuan, co-founder and CEO, Spear Bio is an innovative leader in providing scalable solutions for ultra-sensitive protein biomarker measurements. Its proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar level from sub-microliter sample volume.
FinSMEs
29/07/2024